Fate Therapeutics (FATE) Misses Q1 EPS by 4c
Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.